Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample(Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) - Global Forecast to 2028
The point of care diagnostics market is epected to reach USD 77.8 billion fby 2028 from an estimated USD 49.7 Bn at a CAGR of 9.4% during the forecast period (2023–2028).The gobal rising burden of... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryThe point of care diagnostics market is epected to reach USD 77.8 billion fby 2028 from an estimated USD 49.7 Bn at a CAGR of 9.4% during the forecast period (2023–2028).The gobal rising burden of various helath conditions including diabetes, cardiovascular diseases, infectious diseases and the growing demand for early detection and monitoring of these of these diseases are likely to boost the adoption of PoC tetsing devices. Additionally, technological adcamcements, hleathacre policies promoting decentralized testing and emergence of small PoC manufacturers in emerging countries are likely to booost the growth of market during the forecast period.“Infectious disease testing products segment of point of care diagnostics market to grow with the highest CAGR in the forecast period.” Based on products, the infectious disease tetsing products segemnet is anticipated to grow at a signficant rate during the forecast period.Increasing number of infectious disease such as HIV, tuberculosis, respiratory infections, coupled with the growing availability & awareness of POC testing for infectious diseases are likely to prope the segment growth “The clinical laboratories segment captired the largest market share of point of care diagnostics market in 2022” On the basis of end users, the point-of-care and rapid diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians’ offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users. Clinical laboratories are the primary end users of point-of-care testing a they handle hgh volume of testing, accelerating the demand for point of care diagnostics devices.Moreover, the rapid exoansion of clinical laboratories and presence of advanced PoC products in cinical laboratory settings are likely to promote the growth of the segment North America accounted for the largest share of the point of care diagnostics market by region. The global rpoint of care diagnostics market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for PoC products and services , whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The largest share of North America can be attributed to the rapid adoption of advanced diagnostic technologies, increases collaboration among rapid kits manufacturers and healthacre facilities, favorable reimbursement models, and well established healthacre infrastructure A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16% • By Designation: C-level–10%, Director-level–14%, and Others–76% • By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3% The major players operating in the point-of-care diagnostics market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), and Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), EKF Diagnostics Holdings plc) Research Coverage This report studies the point-of-care diagnostics market based on product, platform, mode of purchase, sample, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence. This report provides insights on the following pointers: Analayis of Key divers (rising prevalnce of infectious and chronic disease, growing adoption of self tetssing kits, helathacre decentralization, rising number of CLIA-wavier Poc Tests), restriants (rising pricing pressure on PoC manufactures, stringent regulatory approval procedures for new PoC devices), Opportunities (emerging markets, emerging technologies, sucha s mucrofuidics) , Challenge (Training & education in low resource countries) Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point-of-care diagnostics market Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point-of-care diagnostics market Market Development: Comprehensive information on lucrative emerging regions Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point-of-care diagnostics market Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players. Table of Contents1 INTRODUCTION 341.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.2.1 INCLUSIONS & EXCLUSIONS 35 1.3 STUDY SCOPE 37 1.3.1 MARKETS COVERED 37 1.3.2 REGIONS COVERED 38 1.3.3 YEARS CONSIDERED 38 1.3.4 CURRENCY CONSIDERED 38 1.4 KEY STAKEHOLDERS 39 1.5 SUMMARY OF CHANGES 39 1.6 RECESSION IMPACT 40 2 RESEARCH METHODOLOGY 41 2.1 RESEARCH DATA 41 FIGURE 1 RESEARCH DESIGN 41 2.1.1 SECONDARY RESEARCH 42 2.1.2 PRIMARY RESEARCH 43 2.1.2.1 Key data from primary sources 43 2.1.2.2 Key industry insights 44 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44 FIGURE 3 BREAKDOWN OF PRIMARIES 45 2.2 MARKET SIZE ESTIMATION 45 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46 2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION 46 2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION 47 FIGURE 5 POINT-OF-CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY 48 2.2.3 PRIMARY RESEARCH VALIDATION 48 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 49 FIGURE 6 DATA TRIANGULATION METHODOLOGY 49 2.4 RESEARCH LIMITATIONS 50 2.5 RECESSION IMPACT ANALYSIS 51 TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 51 3 EXECUTIVE SUMMARY 52 FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 52 FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 (USD MILLION) 53 FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION) 53 FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 54 FIGURE 11 GEOGRAPHIC SNAPSHOT OF POINT-OF-CARE DIAGNOSTICS MARKET 55 4 PREMIUM INSIGHTS 56 4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 56 FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 56 4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 57 FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 57 4.3 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (2022) 58 FIGURE 14 OTC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58 4.4 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 58 FIGURE 15 LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58 4.5 POINT-OF-CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59 FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 FIGURE 17 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 5.2.1 DRIVERS 61 5.2.1.1 Rising incidence of infectious diseases 61 FIGURE 18 REGIONAL INCIDENCE OF HIV (2022) 61 5.2.1.2 Increasing prevalence of target conditions 62 5.2.1.3 Favorable government initiatives for POC testing 62 5.2.1.4 Rising number of CLIA-waived POC tests 63 TABLE 2 RECENT WAIVERS FOR PRODUCTS 63 5.2.2 RESTRAINTS 64 5.2.2.1 Pricing pressure on POC manufacturers 64 5.2.2.2 Stringent regulatory approval process for product commercialization 64 5.2.3 OPPORTUNITIES 65 5.2.3.1 High growth potential of emerging markets 65 5.2.3.2 Decentralization of healthcare 65 5.2.3.3 Innovative product development 66 5.2.4 CHALLENGES 66 5.2.4.1 Inadequate standardization with centralized lab methods 66 5.2.4.2 Limited awareness in emerging markets 67 5.2.4.3 Premium pricing of novel platforms 67 5.3 TECHNOLOGY ANALYSIS 68 5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES 68 5.3.2 STROKE/CARDIAC MARKERS 68 5.3.3 THYROID TESTING 68 5.3.4 DNA TESTING 69 5.3.5 ENDOCRINE TESTING 69 5.3.6 RESPIRATORY DIAGNOSTICS 69 5.4 REGULATORY LANDSCAPE 70 TABLE 3 REGULATORY BODIES AND GOVERNMENT AGENCIES 70 5.4.1 KEY REGULATORY GUIDELINES 70 5.4.1.1 US 70 FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES 71 5.4.1.2 Canada 72 FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES 72 5.4.1.3 Europe 72 FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 73 5.4.1.4 Japan 74 FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 74 5.4.1.5 China 74 TABLE 4 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75 5.4.1.6 India 75 FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES 75 5.4.1.7 Brazil 76 FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 76 5.5 VALUE CHAIN ANALYSIS 77 FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES 77 5.6 SUPPLY CHAIN ANALYSIS 78 5.6.1 PROMINENT COMPANIES 78 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 78 5.6.3 END USERS 78 FIGURE 26 SUPPLY CHAIN ANALYSIS 79 5.6.4 PRICING ANALYSIS 79 TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD) 79 FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER 80 5.6.4.1 Average selling price trend 80 TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD) 80 TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD) 81 TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD) 81 5.7 PORTER’S FIVE FORCES ANALYSIS 82 TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 82 5.7.1 BARGAINING POWER OF BUYERS 82 5.7.2 BARGAINING POWER OF SUPPLIERS 82 5.7.3 THREAT OF NEW ENTRANTS 82 5.7.4 THREAT OF SUBSTITUTES 83 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 83 5.8 TRADE DATA 83 TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION) 83 TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION) 84 5.9 REIMBURSEMENT SCENARIO 84 TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING 84 TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING 85 5.10 PATENT ANALYSIS 85 FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–DECEMBER 2023) 85 5.10.1 ECOSYSTEM/MARKET MAP 86 FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET 86 5.10.2 KEY CONFERENCES & EVENTS 86 TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET: LIST OF KEY CONFERENCES & EVENTS (2023−2024) 86 5.11 CASE STUDY ANALYSIS 87 5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 87 TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS 87 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 88 FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 88 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 88 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 88 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS 88 TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%) 89 5.14 BUYING CRITERIA 89 FIGURE 32 KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS 89 TABLE 17 KEY BUYING CRITERIA FOR POC PRODUCTS 89 6 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 90 6.1 INTRODUCTION 91 TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 91 6.2 OTC TESTING PRODUCTS 91 6.2.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 91 TABLE 19 OTC TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 92 6.3 PRESCRIPTION-BASED TESTING PRODUCTS 92 6.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 92 TABLE 20 PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 93 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 94 7.1 INTRODUCTION 95 TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 95 7.2 LATERAL FLOW ASSAYS 95 7.2.1 RISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET 95 TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021–2028 (USD MILLION) 96 7.3 IMMUNOASSAYS 96 7.3.1 UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH 96 TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 97 7.4 MICROFLUIDICS 97 7.4.1 GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET 97 TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2021–2028 (USD MILLION) 98 7.5 DIPSTICKS 98 7.5.1 QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH 98 TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2021–2028 (USD MILLION) 99 7.6 MOLECULAR DIAGNOSTICS 99 TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021–2028 (USD MILLION) 100 TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 100 7.6.1 RT-PCR 100 7.6.1.1 Rising cases of COVID-19 to boost demand 100 TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 101 7.6.2 INAAT 101 7.6.2.1 Cost benefits of INAAT to propel segment growth 101 TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 102 7.6.3 OTHER TECHNOLOGIES 102 TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 102 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE 103 8.1 INTRODUCTION 104 TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 104 8.2 BLOOD SAMPLES 104 8.2.1 HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET 104 TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2021–2028 (USD MILLION) 104 8.3 URINE SAMPLES 105 8.3.1 INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND 105 TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2021–2028 (USD MILLION) 105 8.4 NASAL & OROPHARYNGEAL SWABS 105 8.4.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET 105 TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021–2028 (USD MILLION) 106 8.5 OTHER SAMPLES 106 TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION) 106 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 107 9.1 INTRODUCTION 108 TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108 9.2 GLUCOSE MONITORING PRODUCTS 109 TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 109 TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 110 9.2.1 STRIPS 110 9.2.1.1 Ability to provide single-use measurement testing to drive market 110 TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021–2028 (USD MILLION) 110 9.2.2 METERS 111 9.2.2.1 Ability to adjust therapeutic regimens daily to support market growth 111 TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021–2028 (USD MILLION) 111 9.2.3 LANCETS & LANCING DEVICES 111 9.2.3.1 Provision of multiple depth penetration settings to boost demand 111 TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 112 9.3 COVID-19 TESTING PRODUCTS 112 9.3.1 RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND 112 TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 113 9.4 CARDIOMETABOLIC MONITORING PRODUCTS 113 TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 113 TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 114 9.4.1 CARDIAC MARKER TESTING PRODUCTS 114 9.4.1.1 Rising government initiatives for CVD research to drive market 114 TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 114 9.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 115 9.4.2.1 Technological advancements in monitoring products to support market growth 115 TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 115 9.4.3 HBA1C TESTING PRODUCTS 115 9.4.3.1 Favorable clinical outcomes with long-term monitoring to drive market 115 TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 116 9.5 INFECTIOUS DISEASE TESTING PRODUCTS 117 TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 117 TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 118 9.5.1 HIV TESTING PRODUCTS 118 9.5.1.1 Rising prevalence of HIV to drive market 118 TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 118 9.5.2 RESPIRATORY INFECTION TESTING PRODUCTS 119 9.5.2.1 Rising incidence of respiratory infections to drive market 119 TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 119 9.5.3 HEPATITIS C TESTING PRODUCTS 119 9.5.3.1 Increasing prevalence of viral hepatitis to support market growth 119 TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 120 9.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 120 9.5.4.1 High incidence of UTIs and surgical-site infections to boost demand 120 TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 121 9.5.5 INFLUENZA TESTING PRODUCTS 121 9.5.5.1 Ability to identify A & B viral nucleoprotein antigens to drive market 121 TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 121 9.5.6 TROPICAL DISEASE TESTING PRODUCTS 122 9.5.6.1 Rising incidence of malaria and dengue to support market growth 122 TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 122 9.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 122 TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 123 TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 123 9.5.7.1 Syphilis testing products 123 9.5.7.1.1 Introduction of rapid tests to boost demand 123 TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 124 9.5.7.2 Human papillomavirus (HPV) testing products 124 9.5.7.2.1 Rising uptake of HPV diagnostics and RT-PCR to support market growth 124 TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 125 9.5.7.3 Chlamydia trachomatis testing products 125 9.5.7.3.1 Growing awareness of STI detection to boost demand 125 TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 126 9.5.7.4 Herpes simplex virus (HSV) testing products 126 9.5.7.4.1 Increasing incidence of HSV to support market growth 126 TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 126 9.5.8 TUBERCULOSIS 127 9.5.8.1 Rising prevalence of TB in underserved areas to support market growth 127 TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION) 127 9.5.9 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 127 9.5.9.1 Rising cases among hospitalized patients to boost demand 127 TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021–2028 (USD MILLION) 128 9.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 128 TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 128 9.6 COAGULATION MONITORING PRODUCTS 129 TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 129 TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 130 9.6.1 PT/INR TESTING PRODUCTS 130 9.6.1.1 Ability to detect blood clots to support market growth 130 TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 130 9.6.2 ACT/APTT TESTING PRODUCTS 131 9.6.2.1 Rising cases of dialysis and ESRD to boost demand 131 TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 131 9.7 PREGNANCY & FERTILITY TESTING PRODUCTS 131 TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 131 TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 132 9.7.1 PREGNANCY TESTING PRODUCTS 132 9.7.1.1 Growing preference for home care testing to drive market 132 TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 132 9.7.2 FERTILITY TESTING PRODUCTS 133 9.7.2.1 Growing focus on family planning to boost demand 133 TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 133 9.8 TUMOR/CANCER MARKER TESTING PRODUCTS 133 9.8.1 INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET 133 TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 134 9.9 URINALYSIS TESTING PRODUCTS 134 9.9.1 HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET 134 TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 135 9.10 CHOLESTEROL TESTING PRODUCTS 135 9.10.1 RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND 135 TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 135 9.11 HEMATOLOGY TESTING PRODUCTS 136 9.11.1 PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET 136 TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021–2028(USD MILLION) 136 9.12 DRUGS-OF-ABUSE TESTING PRODUCTS 136 9.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET 136 TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 137 9.13 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS 137 9.13.1 RISING CASES OF THYROID TO BOOST DEMAND 137 TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 137 9.14 FECAL OCCULT TESTING PRODUCTS 138 9.14.1 INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH 138 TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 138 9.15 OTHER PRODUCTS 138 TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 139 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 140 10.1 INTRODUCTION 141 TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 141 10.2 CLINICAL LABORATORIES 141 10.2.1 IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND 141 TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 142 10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES 142 10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET 142 TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION) 143 10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS 143 10.4.1 ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND 143 TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021–2028 (USD MILLION) 143 10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 144 10.5.1 RAPID RESULTS AND END USERS OF POC DIAGNOSTICS 144 TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 144 10.6 HOME CARE SETTINGS AND SELF-TESTING 145 10.6.1 GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET 145 TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021–2028 (USD MILLION) 145 10.7 OTHER END USERS 146 TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 146 11 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 147 11.1 INTRODUCTION 148 TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 148 11.2 NORTH AMERICA 148 11.2.1 NORTH AMERICA: RECESSION IMPACT 148 FIGURE 33 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 149 TABLE 89 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150 TABLE 90 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150 TABLE 91 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 151 TABLE 92 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 151 TABLE 93 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 152 TABLE 94 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 152 TABLE 95 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 153 TABLE 96 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 153 TABLE 97 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 154 TABLE 98 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 154 TABLE 99 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 155 11.2.2 US 155 11.2.2.1 Favorable government support and medical reimbursements to boost demand 155 TABLE 100 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156 11.2.3 CANADA 157 11.2.3.1 Rising incidence of diabetes and cancer to support market growth 157 TABLE 101 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158 11.3 EUROPE 159 11.3.1 EUROPE: RECESSION IMPACT 159 TABLE 102 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159 TABLE 103 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160 TABLE 104 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161 TABLE 105 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161 TABLE 106 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 162 TABLE 107 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 162 TABLE 108 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 163 TABLE 109 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 163 TABLE 110 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 163 TABLE 111 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 164 TABLE 112 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 164 11.3.2 GERMANY 165 11.3.2.1 Rising demand for innovative technologies to propel market 165 TABLE 113 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 166 11.3.3 FRANCE 166 11.3.3.1 Growing public-private collaborations for product development to drive market 166 TABLE 114 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167 11.3.4 UK 168 11.3.4.1 Growing number of accredited diagnostic & hospital laboratories to propel market 168 TABLE 115 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169 11.3.5 ITALY 169 11.3.5.1 Increasing adoption of infectious disease diagnostics to drive market 169 TABLE 116 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 170 11.3.6 SPAIN 170 11.3.6.1 Rising incidence of chronic diseases to support market growth 170 TABLE 117 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 171 11.3.7 REST OF EUROPE 171 TABLE 118 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172 11.4 ASIA PACIFIC 173 11.4.1 ASIA PACIFIC: RECESSION IMPACT 173 FIGURE 34 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 174 TABLE 119 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175 TABLE 120 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176 TABLE 121 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 177 TABLE 122 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 177 TABLE 123 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178 TABLE 124 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178 TABLE 125 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 179 TABLE 126 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 179 TABLE 127 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 179 TABLE 128 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 180 TABLE 129 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 180 11.4.2 JAPAN 181 11.4.2.1 Availability of advanced rapid flu tests to drive market 181 TABLE 130 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 182 11.4.3 CHINA 182 11.4.3.1 Rising incidence of infectious diseases to drive market 182 TABLE 131 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 183 11.4.4 INDIA 184 11.4.4.1 High burden of chronic diseases to propel market 184 TABLE 132 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185 11.4.5 AUSTRALIA 185 11.4.5.1 Increasing research investments for next-gen POC devices to fuel market 185 TABLE 133 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION 186 11.4.6 SOUTH KOREA 187 11.4.6.1 Growing awareness about advanced POC devices to boost demand 187 TABLE 134 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 187 11.4.7 REST OF ASIA PACIFIC 188 TABLE 135 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189 11.5 LATIN AMERICA 190 11.5.1 LATIN AMERICA: RECESSION IMPACT 190 TABLE 136 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190 TABLE 137 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 191 TABLE 138 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 191 TABLE 139 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 192 TABLE 140 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 192 TABLE 141 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 193 TABLE 142 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 193 TABLE 143 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 193 TABLE 144 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 194 TABLE 145 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 194 TABLE 146 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 195 11.5.2 BRAZIL 195 11.5.2.1 Rising prevalence of diabetes to support market growth 195 TABLE 147 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196 11.5.3 MEXICO 197 11.5.3.1 Rising incidence of cancer to drive market 197 TABLE 148 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197 11.5.4 REST OF LATIN AMERICA 198 TABLE 149 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 198 11.6 MIDDLE EAST & AFRICA 199 11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 199 TABLE 150 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199 TABLE 151 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200 TABLE 152 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 200 TABLE 153 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201 TABLE 154 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201 TABLE 155 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 202 TABLE 156 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 202 TABLE 157 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 202 TABLE 158 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 203 TABLE 159 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 203 TABLE 160 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 204 11.6.1.1 GCC Countries 204 11.6.1.1.1 Improvements in healthcare infrastructure to drive market 204 TABLE 161 GCC COUNTRIES: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205 11.6.2 REST OF MIDDLE EAST & AFRICA 205 TABLE 162 REST OF AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 206 TABLE 163 REST OF MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 207 12 COMPETITIVE LANDSCAPE 208 12.1 INTRODUCTION 208 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 208 FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET 209 12.3 REVENUE SHARE ANALYSIS 210 FIGURE 36 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET (2022) 210 12.4 MARKET SHARE ANALYSIS 211 FIGURE 37 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 211 12.5 COMPANY EVALUATION MATRIX 212 12.5.1 STARS 212 12.5.2 EMERGING LEADERS 212 12.5.3 PERVASIVE PLAYERS 212 12.5.4 PARTICIPANTS 212 FIGURE 38 COMPANY EVALUATION MATRIX 213 12.5.5 COMPANY FOOTPRINT 214 12.5.5.1 Product & regional footprint 214 TABLE 164 OVERALL FOOTPRINT 214 TABLE 165 PRODUCT FOOTPRINT 215 TABLE 166 REGIONAL FOOTPRINT 216 12.6 START-UP/SME EVALUATION MATRIX 217 12.6.1 PROGRESSIVE COMPANIES 217 12.6.2 RESPONSIVE COMPANIES 217 12.6.3 DYNAMIC COMPANIES 217 12.6.4 STARTING BLOCKS 217 FIGURE 39 START-UP/SME EVALUATION MATRIX 218 12.6.5 COMPETITIVE BENCHMARKING 219 TABLE 167 POINT-OF-CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 219 12.7 COMPETITIVE SCENARIO 220 12.7.1 PRODUCT LAUNCHES & APPROVALS 220 TABLE 168 POINT-OF-CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–NOVEMBER 2023) 220 12.7.2 DEALS 221 TABLE 169 POINT-OF-CARE DIAGNOSTICS MARKET: DEALS (JANUARY 2020–NOVEMBER 2023) 221 12.7.3 OTHER DEVELOPMENTS 222 TABLE 170 POINT-OF-CARE DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023) 222
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社のMedical Devices分野での最新刊レポート
本レポートと同じKEY WORD(diagnostics)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|